Daniel Passeri
Vorstandsvorsitzender bei CUE BIOPHARMA, INC.
Vermögen: 189 755 $ am 30.04.2024
Aktive Positionen von Daniel Passeri
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CUE BIOPHARMA, INC. | Direktor/Vorstandsmitglied | 01.08.2016 | - |
| Vorstandsvorsitzender | 01.08.2016 | - | |
| Präsident | 01.08.2016 | 07.10.2019 |
Karriereverlauf von Daniel Passeri
Ehemalige bekannte Positionen von Daniel Passeri
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CURIS, INC. | Direktor/Vorstandsmitglied | 01.09.2011 | 01.06.2016 |
| Vorstandsvorsitzender | 01.09.2001 | 02.06.2014 | |
| Corporate Officer/Principal | 01.11.2000 | 01.09.2001 | |
| Präsident | 01.09.2001 | 01.02.2013 | |
Genomic Medicine, Inc.
 Genomic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Part of GenoMed, Inc., Genomic Medicine, Inc. is a private company that researches and studies disease causing genes. The company is based in St. Louis, MO. Genomic Medicine was acquired by GenoMed, Inc. on November 29, 2001 for $1.25 million. | Corporate Officer/Principal | 01.12.2014 | 01.06.2015 |
Gene Logic, Inc.
 Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Corporate Officer/Principal | 01.03.1997 | 01.11.2000 |
| Boehringer Mannheim Pharmaceuticals Corp. | Corporate Officer/Principal | 01.03.1997 | 01.03.1997 |
Xequel Bio, Inc.
 Xequel Bio, Inc. Pharmaceuticals: MajorHealth Technology Xequel Bio, Inc. operates as a biopharmaceutical company. It develops drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company was founded by Gautam Sudhir Ghatnekar in 2005 and is headquartered in Mount Pleasant, SC. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Daniel Passeri
| Northeastern University | Undergraduate Degree |
| Imperial College London | Graduate Degree |
| George Washington University Law School | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 9 |
| Vereinigtes Königreich | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Director/Board Member | 3 |
| Chief Executive Officer | 2 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 4 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CURIS, INC. | Health Technology |
| CUE BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Gene Logic, Inc.
Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Health Technology |
| Boehringer Mannheim Pharmaceuticals Corp. | |
Xequel Bio, Inc.
Xequel Bio, Inc. Pharmaceuticals: MajorHealth Technology Xequel Bio, Inc. operates as a biopharmaceutical company. It develops drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company was founded by Gautam Sudhir Ghatnekar in 2005 and is headquartered in Mount Pleasant, SC. | Health Technology |
Genomic Medicine, Inc.
Genomic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Part of GenoMed, Inc., Genomic Medicine, Inc. is a private company that researches and studies disease causing genes. The company is based in St. Louis, MO. Genomic Medicine was acquired by GenoMed, Inc. on November 29, 2001 for $1.25 million. | Commercial Services |
- Börse
- Insiders
- Daniel Passeri
- Erfahrung
